KLRS earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -1.89. Updated 2026-07-23.
Kalaris Therapeutics (KLRS) Research Hub
Kalaris Therapeutics (KLRS) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.38 USD (-2.59%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.89, market cap 0.07B. This hub links to the full technical, earnings and options research available for KLRS.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.38 USD (-2.59%) |
| 52-week range | 3.03 USD – 4.91 USD |
| Trend regime | Range |
| 14-day RSI | 25.5 (Oversold) |
| Trailing P/E | -1.89 |
| Market cap | 0.07B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for KLRS
Covered Call on KLRS: how it works, illustrative setup around the real 3.38 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KLRS: how it works, illustrative setup around the real 3.38 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KLRS: how it works, illustrative setup around the real 3.38 USD price, max profit/loss, breakeven and when to use it. Educational.
KLRS technical analysis: range, last 3.38 USD, RSI 25.5, 52w range 3.03 USD–4.91 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KLRS in?
Kalaris Therapeutics (KLRS) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KLRS in an uptrend or downtrend?
As of 2026-09-11, KLRS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KLRS's trailing P/E ratio?
KLRS's trailing P/E is -1.89, with a market cap of 0.07B. See the earnings research page for full valuation detail.
When does KLRS next report earnings?
KLRS is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.5 USD.